Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. 1997

M Nijhuis, and R Schuurman, and D de Jong, and R van Leeuwen, and J Lange, and S Danner, and W Keulen, and T de Groot, and C A Boucher
Eijkman-Winkler Institute, Department of Virology, University Hospital Utrecht, Netherlands.

Exposure of human immunodeficiency virus to the nucleoside analogue lamivudine (3TC) rapidly selects for resistant variants with a valine at codon 184 (M184V) in the catalytic site of reverse transcriptase. In vitro, 184V demonstrated increased enzyme fidelity and suppressed zidovudine resistance. Clinical trials demonstrated that 3TC-zidovudine combination therapy results in a strong and sustained antiviral response. To investigate the role of 184V on in vivo virus evolution, the effect of zidovudine addition in 3TC-pretreated patients harboring 184V was studied. In vivo, no significant change in fidelity was observed with 184V, shown by generation of the classical pattern of zidovudine mutations. Of interest, in contrast to zidovudine monotherapy, in which just one substitution is sufficient for in vivo development of significant zidovudine resistance, multiple substitutions are required for the same level of zidovudine resistance in strains harboring 184V. This need for multiple substitutions may be one of the mechanisms explaining the sustained antiretroviral response of the 3TC-zidovudine combination.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U

Related Publications

M Nijhuis, and R Schuurman, and D de Jong, and R van Leeuwen, and J Lange, and S Danner, and W Keulen, and T de Groot, and C A Boucher
March 1994, The Journal of infectious diseases,
M Nijhuis, and R Schuurman, and D de Jong, and R van Leeuwen, and J Lange, and S Danner, and W Keulen, and T de Groot, and C A Boucher
July 1994, Antimicrobial agents and chemotherapy,
M Nijhuis, and R Schuurman, and D de Jong, and R van Leeuwen, and J Lange, and S Danner, and W Keulen, and T de Groot, and C A Boucher
April 1993, The New England journal of medicine,
M Nijhuis, and R Schuurman, and D de Jong, and R van Leeuwen, and J Lange, and S Danner, and W Keulen, and T de Groot, and C A Boucher
August 2010, The Journal of general virology,
M Nijhuis, and R Schuurman, and D de Jong, and R van Leeuwen, and J Lange, and S Danner, and W Keulen, and T de Groot, and C A Boucher
March 2000, Antimicrobial agents and chemotherapy,
M Nijhuis, and R Schuurman, and D de Jong, and R van Leeuwen, and J Lange, and S Danner, and W Keulen, and T de Groot, and C A Boucher
February 1994, The Journal of infectious diseases,
M Nijhuis, and R Schuurman, and D de Jong, and R van Leeuwen, and J Lange, and S Danner, and W Keulen, and T de Groot, and C A Boucher
July 2008, Journal of virology,
M Nijhuis, and R Schuurman, and D de Jong, and R van Leeuwen, and J Lange, and S Danner, and W Keulen, and T de Groot, and C A Boucher
May 1998, Journal of virology,
M Nijhuis, and R Schuurman, and D de Jong, and R van Leeuwen, and J Lange, and S Danner, and W Keulen, and T de Groot, and C A Boucher
November 2001, The Journal of infectious diseases,
M Nijhuis, and R Schuurman, and D de Jong, and R van Leeuwen, and J Lange, and S Danner, and W Keulen, and T de Groot, and C A Boucher
January 1992, Current topics in microbiology and immunology,
Copied contents to your clipboard!